| 2026-05-07 | 10-Q | 10.1 | Amendment Four to the Collaboration Agreement, dated February 20, 2026, by and between Adimab, LLC and the Registrant |
|---|
| 2026-03-10 | 10-K | 10.20 | Non-Employee Director Compensation Policy. |
|---|
| 2025-08-07 | 10-Q | 10.1 | License Agreement, dated as of June 4, 2025, by and between Cullinan Therapeutics, Inc. and Chongqing Genrix Biopharmaceutical Co., Ltd. |
|---|
| 2025-05-08 | 10-Q | 10.2 | Non-Employee Director Compensation Policy. |
|---|
| 2025-05-08 | 10-Q | 10.1 | Amendment Three to the Collaboration Agreement, dated July 11, 2024, by and between Adimab, LLC and the Registrant. |
|---|
| 2025-02-27 | 10-K | 10.34 | Third Amendment to Exclusive Patent License Agreement, dated December 20, 2023, by and between the Massachusetts Institute of Technology and Cullinan Amber Corp. |
|---|
| 2025-02-27 | 10-K | 10.9 | Amendment Two to the Collaboration Agreement, dated July 11, 2024, by and between Adimab, LLC and the Registrant. |
|---|
| 2025-02-27 | 10-K | 10.8 | Amendment One to the Collaboration Agreement, dated April 30, 2024, by and between Adimab, LLC and the Registrant. |
|---|
| 2024-05-15 | 10-Q | 10.1 | Separation and Transition Agreement, effective as March 28, 2024, by and between the Registrant and Jeffrey Trigilio. |
|---|
| 2024-04-29 | 8-K | 10.1 | Employment Agreement, effective April 29, 2024, between Cullinan Therapeutics, Inc. and Mary Kay Fenton |
|---|
| 2024-04-16 | 8-K | 10.3 | Form of Pre-Funded Warrant |
|---|
| 2024-04-16 | 8-K | 10.2 | Form of Registration Rights Agreement, dated April 15, 2024, by and among Cullinan Therapeutics, Inc. and the purchasers party thereto |
|---|
| 2024-04-16 | 8-K | 10.1 | Form of Stock Purchase Agreement, dated April 15, 2024, by and among Cullinan Therapeutics, Inc. and the purchasers party thereto |
|---|
| 2024-03-14 | 10-K | 10.32 | Form of Restricted Stock Unit Award Agreement |
|---|
| 2023-11-08 | 10-Q | 10.1 | Amendment No. 1 to Employment Agreement, by and between the Registrant and Nadim Ahmed |
|---|
| 2023-08-10 | 10-Q | 10.2 | Non-Employee Director Compensation Policy |
|---|
| 2023-08-10 | 10-Q | 10.1 | Consulting Agreement, dated June 8, 2023, by and between the Registrant and Patrick Baeuerle |
|---|
| 2023-05-11 | 10-Q | 10.2 | License and Collaboration Agreement, dated February 13, 2023, by and between the Registrant and Harbour BioMed US Inc. |
|---|
| 2023-03-09 | 10-K | 10.27 | Amendment Number 1 to Royalty Transfer Agreement, dated June 6, 2022, by and among the Registrant, MPM Oncology Charitable Foundation, Inc., and the UBS Optimus Foundation |
|---|
| 2023-03-09 | 10-K | 10.26 | Second Amendment to Exclusive Patent License Agreement, dated December 20, 2022, by and between the Massachusetts Institute of Technology and Cullinan Amber Corp. |
|---|
| 2023-03-09 | 10-K | 10.25 | Form of Stock Purchase and Transfer Agreement for Individual Transferors |
|---|
| 2023-03-09 | 10-K | 10.24 | Form of Stock Purchase and Transfer Agreement for Institutional Transferors |
|---|
| 2023-03-09 | 10-K | 10.23 | Employment Agreement, effective January 7, 2021, between the Registrant and Jeffrey Trigilio |
|---|
| 2023-01-19 | 8-K | 10.1 | Exchange Agreement, dated January 17, 2023, by and among Cullinan Oncology, Inc. and the Stockholders named therein |
|---|
| 2022-08-10 | 10-Q | 10.3 | Performance Stock Unit Award Agreement, dated June 9, 2022, by and between the Registrant and Nadim Ahmed |
|---|
| 2022-08-10 | 10-Q | 10.2 | Co-Development Agreement, dated June 21, 2022, by and between the Registrant and Taiho Oncology, Inc. |
|---|
| 2022-08-10 | 10-Q | 10.1 | Share Purchase Agreement, dated May 11, 2022, by and among the Registrant, Taiho Pharmaceutical Co. Ltd. and Cullinan Pearl Corp. |
|---|
| 2022-03-17 | 10-K | 10.23 | Separation Agreement, effective as of October 18, 2021, by and between the Registrant and Owen Hughes. |
|---|
| 2022-03-03 | 8-K | 10.1 | Employment Agreement, effective February 28, 2022, between Cullinan Oncology, Inc. and Jeffrey Jones |
|---|
| 2021-10-18 | 8-K | 10.1 | Employment Agreement, effective as of October 18, 2021, by and between the Company and Nadim Ahmed. |
|---|
| 2021-08-10 | 10-Q | 10.1 | Consulting Agreement, dated May 20, 2021, among the Registrant and Jon Wigginton, M.D. |
|---|